Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Nuplazid (pimavanserin) for the treatment of Parkinson’s Disease Psychosis (PDP)

Drug (Brand/Generic)

Nuplazid (pimavanserin)

Company/Licensee

Acadia Pharmaceuticals

Therapy Class

Serotonin inverse antagonist

Current Indication

Parkinson’s Disease Psychosis

Market Sector

Central nervous system (CNS)

Development Status

Approved in the US
Expand

Go Top